Dr. Carla B. Golden

Claim this profile

UCSF Benioff Children's Hospital Oakland

Expert in Cancer
Expert in Lymphoma
43 reported clinical trials
83 drugs studied

Area of expertise

1Cancer
Global Leader
Carla B. Golden has run 25 trials for Cancer. Some of their research focus areas include:
Stage I
Stage IV
Stage II
2Lymphoma
Global Leader
Carla B. Golden has run 16 trials for Lymphoma. Some of their research focus areas include:
Philadelphia chromosome positive
BCR-ABL1 fusion positive
ABL-class fusion positive

Affiliated Hospitals

Image of trial facility.
UCSF Benioff Children's Hospital Oakland
Image of trial facility.
Children's Hospital And Research Center At Oakland

Clinical Trials Carla B. Golden is currently running

Image of trial facility.

Genetic Testing-Directed Therapy

for Pediatric Cancer

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Image of trial facility.

Inotuzumab Ozogamicin

for Acute Lymphoblastic Leukemia

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3

More about Carla B. Golden

Clinical Trial Related7 years of experience running clinical trials · Led 43 trials as a Principal Investigator · 14 Active Clinical Trials
Treatments Carla B. Golden has experience with
  • Cyclophosphamide
  • Laboratory Biomarker Analysis
  • Etoposide
  • Cytology Specimen Collection Procedure
  • Methotrexate
  • Vincristine Sulfate

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Carla B. Golden specialize in?
Carla B. Golden focuses on Cancer and Lymphoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Carla B. Golden currently recruiting for clinical trials?
Yes, Carla B. Golden is currently recruiting for 9 clinical trials in Oakland California. If you're interested in participating, you should apply.
Are there any treatments that Carla B. Golden has studied deeply?
Yes, Carla B. Golden has studied treatments such as Cyclophosphamide, Laboratory Biomarker Analysis, Etoposide.
What is the best way to schedule an appointment with Carla B. Golden?
Apply for one of the trials that Carla B. Golden is conducting.
What is the office address of Carla B. Golden?
The office of Carla B. Golden is located at: UCSF Benioff Children's Hospital Oakland, Oakland, California 94609 United States. This is the address for their practice at the UCSF Benioff Children's Hospital Oakland.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.